Brief: Reviva Announces Positive Topline Results From Global Pivotal Phase 3 RECOVER Trial Of Brilaroxazine In Schizophrenia

Reviva Pharmaceuticals Holdings

30/10/2023 11:33

Oct 30 (Reuters) - Reviva Pharmaceuticals Holdings, Inc.
 RVPH.O :
    * REVIVA ANNOUNCES POSITIVE TOPLINE RESULTS FROM GLOBAL
PIVOTAL
PHASE 3 RECOVER TRIAL OF BRILAROXAZINE IN SCHIZOPHRENIA
    * REVIVA PHARMACEUTICALS HOLDINGS, INC.: STUDY SUCCESSFULLY
MET
PRIMARY ENDPOINT
    * REVIVA : STATISTICALLY SIGNIFICANT, CLINICALLY MEANINGFUL
REDUCTIONS IN ALL MAJOR SYMPTOM DOMAINS & SECONDARY ENDPOINTS AT
WEEK 4 WITH 50 MG OF BRILAROXAZINE VERSUS. PLACEBO
    * REVIVA PHARMACEUTICALS HOLDINGS, INC.: TOPLINE DATA FROM
1-YEAR
OPEN-LABEL EXTENSION (OLE) TRIAL EXPECTED Q4 2024

Source text for Eikon:  ID:nGNX4GPmGm 
Further company coverage:  RVPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))